{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalComment":"If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.","statisticalMethod":"Regression, Logistic"},{"ciNumSides":"TWO_SIDED","groupDescription":"Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.002","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalComment":"If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.","statisticalMethod":"Regression, Logistic"},{"ciNumSides":"TWO_SIDED","groupDescription":"Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.001","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalComment":"If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.","statisticalMethod":"Regression, Logistic"},{"ciNumSides":"TWO_SIDED","groupDescription":"Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.015","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalComment":"If logistic regression sample size requirements are not met, the p-value from Fisher's exact test is used instead.","statisticalMethod":"Regression, Logistic"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.0"},{"groupId":"OG001","value":"20.1"},{"groupId":"OG002","value":"28.2"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.1"},{"groupId":"OG001","value":"23.0"},{"groupId":"OG002","value":"29.4"}]}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"176"},{"groupId":"OG001","value":"174"},{"groupId":"OG002","value":"177"}],"units":"Participants"}],"description":"ACR50 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 Responder is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinue study or drug or are rescued before analysis time point are deemed non-responders.","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"NUMBER","populationDescription":"mITT population includes all randomized participants who received at least 1 dose of the study drug. Participants were analyzed according to the study drug to which they were randomized. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using NRI.","reportingStatus":"POSTED","timeFrame":"Week 12 and Week 24","title":"Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}